Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70075 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Stalin Canizares und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transplant Surgery, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Abatacept, Tacrolimus, Graft Rejection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Calcineurin inhibitors have been the choice for maintenance immunosuppression (IS) in kidney transplant recipients (KTR), but they are associated with nephrotoxicity and metabolic side effects. We aim to compare the long‐term outcomes of KTR on belatacept (bela) versus tacrolimus (tac) IS, in all KTRs and various subgroups. Using the UNOS‐STAR files, we identified adult first‐KTR from 2010 to 2022. Patients were categorized based on maintenance‐IS at index transplant admission by creating a propensity score matched cohort at 1:5 rate using several clinical characteristics. Primary outcomes included patient death, graft failure (GF), and death‐censored graft failure (DCGF). Secondary outcomes included delayed graft function (DGF), acute‐rejections (AR) within a year, and serum creatinine (Cr) at 1‐year. The propensity‐matched cohort included KTRs on bela ( N = 2612) and tac ( N = 12760). There was no significant difference in the hazard ratio of death (1.03 [0.92, 1.14]), GF (1.07 [0.97, 1.17]), or DCGF (1.11 [0.98, 1.25]). A sensitivity analysis comparing a propensity‐matched cohort of bela + tac ( n = 2033) versus tac ( n = 9004); demonstrated significantly reduced risks of death (0.87 [0.76–1.00], p = 0.043) and GF (0.73 [0.64–0.83] p < 0.001) compared to those on Tac alone. In conclusion, bela + tac seems to be a nephron‐sparing and rejection‐lowering IS regimen with overall improved graft and patient outcomes when compared to the current standard of tacrolimus. Larger Randomized Controlled studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transplant Surgery, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Transplant Nephrology, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
- Department of Transplant Nephrology, Transplant Surgery Institute, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Stalin Canizares, Adriana Montalvan, Devin Eckhoff, Kalathil K Sureshkumar, Bhavna Chopra
Zitieren
APA
Canizares, S., Montalvan, A., Eckhoff, D., Sureshkumar, K. K., & Chopra, B. (2025). Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis. Clinical Transplantation. https://doi.org/10.1111/ctr.70075
Vancouver
Canizares S, Montalvan A, Eckhoff D, Sureshkumar KK, Chopra B. Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis. Clinical Transplantation. 2025. doi:10.1111/ctr.70075
BibTeX
@article{Canizares2025,
author = {Canizares, Stalin and Montalvan, Adriana and Eckhoff, Devin and Sureshkumar, Kalathil K and Chopra, Bhavna},
title = {Long Term Outcomes of Transplant Recipients Comparing Belatacept vs. Tacrolimus: A UNOS Database Analysis},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70075}
}
EUVIMED